Meeting Banner
Abstract #0005

Hyperpolarised xenon-129 MR spectroscopy and diffusion-weighted xenon-129 MRI at baseline in patients with interstitial lung disease

James A Eaden1,2, Paul JC Hughes1, Ho-Fung Chan1, Oliver Rodgers1, Guilhem J Collier1, Graham Norquay1, Matthew Austin1, Laurie J Smith1, Jim Lithgow1, Nicholas D Weatherley1, Helen Marshall1, Andrew J Swift1,2, Stephen A Renshaw1,2, Colm T Leonard3,4, Sarah Skeoch3, Nazia Chaudhuri3,4, Geoff JM Parker5, Stephen M Bianchi2, and Jim M Wild1

1The University of Sheffield, Sheffield, United Kingdom, 2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, 3The University of Manchester, Manchester, United Kingdom, 4The University of Manchester NHS Foundation Trust, Manchester, United Kingdom, 5Bioxydyn Ltd, Manchester, United Kingdom

Preliminary findings are presented from a prospective, longitudinal, multicentre MRI biomarker study of patients presenting with interstitial lung disease (ILD) including drug induced ILD, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis and connective tissue disease ILD. At the time of writing, 27 patients have undergone baseline hyperpolarised xenon-129 (129Xe) MR spectroscopy (MRS) and 129Xe diffusion-weighted MRI. Our findings suggest significant differences in mean 129Xe apparent diffusion coefficient between the ILD subtypes at baseline but no significant differences in the red blood cell / tissue plasma ratio from dissolved 129Xe MRS. We also demonstrate correlation between pulmonary function tests and 129Xe MRI measures.

This abstract and the presentation materials are available to members only; a login is required.

Join Here